Cormorant Asset Management, LP Adverum Biotechnologies, Inc. Call Options Transaction History

Cormorant Asset Management, LP

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $1.54 Million - $3.67 Million	-300,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $1.57 Million - $4.77 Million	300,000 New	300,000 $1.64 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $449M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.